Detalhe da pesquisa
1.
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
J Thorac Oncol
; 19(6): 941-953, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38159809